Combination therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor (like lung, breast, stomach, or bladder cancer) that has spread or that other treatments have not helped.
- You are well enough to carry out daily activities (performance status 0 or 1).
- You can provide a tumor tissue sample (new or from within the last 3 years) for testing.
- You have not had certain prior treatments, such as immunotherapy (PD-1/PD-L1 inhibitors) or specific targeted antibody drugs.
- Your major organs (like bone marrow, liver, and kidneys) are working well enough, and you do not have serious heart, brain, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This study tests a new drug called CVL006 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how well it works against different types of cancer.
This study tests a combination of two drugs (CVL006 and 9MW2821) for advanced solid tumors, especially head and neck cancer. The goal is to see if the combination can shrink or control the cancer.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.